Skip to main content
SpringerLink
Log in

Kolorektales Karzinom

  • Chapter
Therapiekonzepte Onkologie

  • 69 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer Statistics. CA Cancer J Clin 47:5–27

    Article  PubMed  CAS  Google Scholar 

  2. Trock B, Lanza E, Greenwald P (1990) Dietary fiber, vegetables and colon cancer. critical review and meta-analysis of the epidemiologic evidence. J Natl Cancer Inst 82:650–661

    Article  PubMed  CAS  Google Scholar 

  3. Willett WC, Stamfer MJ, Colditz G et al. (1990) Relation of meat, fat, and fibe intake to the risk of colon cancer in a prospective study among women. N Engl J Med 323:1664–1672

    Article  PubMed  CAS  Google Scholar 

  4. Giovannucci E, Stampfer MJ, Colditz G et al. (1992) Relationship of diet to risk of colorectal adenoma in mem. J Natl Cancer Inst 84:91–98

    Article  PubMed  CAS  Google Scholar 

  5. Howe GR, Benito E, Castelleto R et al. (1992) Dietary intake of fiber and decreased risk of cancers of the colon and rectum. Evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst 84:1887–1896

    Article  PubMed  CAS  Google Scholar 

  6. Vasen HFA, Mecklin JP, Kahn PM, Lynch HT (1991) Hereditary non-polyposis colorectal cancer. Lancet 338:877

    Article  Google Scholar 

  7. Hamilton SR (1993) The molecular genetics of colorectal neoplasia. Gastroenterology 105:3–7

    PubMed  CAS  Google Scholar 

  8. Jessup JM, Menck HR, Fremgen A, Winchester DP (1997) Diagnosing Colorectal Carcinoma: Clinical and Molecular Approaches. CA Cancer J Clin 47:70–92

    Article  PubMed  CAS  Google Scholar 

  9. Markowitz AJ, Winawer SJ (1997) Management of colorectal polyps. CA Cancer J Clin 47:93–112

    Article  PubMed  CAS  Google Scholar 

  10. Muto T, Bussey HJR, Morson BC (1975) The evolution of cancer of the colon and rectum. Cancer 36:2270–3351

    Article  Google Scholar 

  11. Stryker SJ, Wolff BG, Culp CE et al. (1987) Natural history of untreated colonic polyps. Gastroenterology 93:1009–1013

    PubMed  CAS  Google Scholar 

  12. Winawer SJ, Zauber AG, Ho MN et al. (1993) Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 329:1977–1981

    Article  PubMed  CAS  Google Scholar 

  13. Blenkinsopp WK, Stewart-Brown S, Blesowsky L et al. (1981) Histopathology reporting in large bowel cancer. J Clin Pathol 34:509–513

    Article  PubMed  CAS  Google Scholar 

  14. Dukes CE (1932) The classification of cancer of the rectum. J Pathol 35:323–332

    Article  Google Scholar 

  15. Astler VB, Coller FA (1954) The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139:846–851

    Article  PubMed  CAS  Google Scholar 

  16. TNM-Klassifikation maligner Tumoren, 5. Auflage (1997) In: Wittekind CH, Wagner G (Hrsg), Springer Verlag

    Google Scholar 

  17. Nathanson SD, Schultz L, Tilley B et al. (1986) Carcinoma of the colon and rectum: A comparison of staging classifications. Ann Surg 52:428–433

    CAS  Google Scholar 

  18. Jass JR, Mukawa K, Goh HS et al. (1989) Clinical importance of DNA content in rectal cancer measured by flow cytometry. J Clin Pathol 42:254–259

    Article  PubMed  CAS  Google Scholar 

  19. Witzig TE, Loprinzi CL, Gonchosoff NJ et al. (1991) DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stage B2 and C colorectal adenocarcinoma. Cancer 68:879–888

    Article  PubMed  CAS  Google Scholar 

  20. Hamelin R, Laurent-Puig P, Olschwang S et al. (1994) Association of P53 mutations with short survival in colorectal cancer. Gastroenterology 106:42–48

    PubMed  CAS  Google Scholar 

  21. Bosari S, Viale G, Bossi P et al. (1994) Cytoplasmatic accumulation of P53 protein: an independent progonstic indicator adenocarcinomas. J Natl Cancer Inst 86:681–687

    Article  PubMed  CAS  Google Scholar 

  22. Jen J, Kim H, Piantadosi SP et al. (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213–221

    Article  PubMed  CAS  Google Scholar 

  23. Willett CG, Tepper JE, Cohen AM et al. (1984) Failure patterns following curative resection of colonic carcinoma. Ann Surg 200:685–690

    Article  PubMed  CAS  Google Scholar 

  24. Rich T, Gunderson LL, Lew R et al. (1983) Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 52:1317–1329

    Article  PubMed  CAS  Google Scholar 

  25. Read TE, Read JD, Butterfly LF (1997) Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy. N Engl J Med 336:8–12

    Article  PubMed  CAS  Google Scholar 

  26. Rothenberg DA, Buie WD (1994) Local regional staging of rectal cancer. In: Cohen AM, Winawer SJ (eds) Cancer of the Colon, Rectum and Anus. New York, McGraw-Hill, pp 521–531

    Google Scholar 

  27. de Mello J, Struthers L, Turner R et al. (1983) Multivariate analysis as acides to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer 48: 341–348

    Article  PubMed  Google Scholar 

  28. Moertel CG, O’Fallon JR, Go VL et al. (1986) The preoperative carcinoembryonic antigen test in the diagnosis, staging and prognosis of colorectal cancer. Cancer 58:603–610

    Article  PubMed  CAS  Google Scholar 

  29. August DA, Ottow RT, Sugarbaker PH (1984) Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3:303–324

    Article  PubMed  CAS  Google Scholar 

  30. Staab HJ, Anderer FA, Stumpf E et al. (1985) Eighty-four second look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg 179: 198–204

    Article  Google Scholar 

  31. Denstman F, Rosen L, Khubchandani IT et al. (1986) Comparing predictive decision rule in postoperative CEA monitoring. Cancer 58:2089–2095

    Article  PubMed  CAS  Google Scholar 

  32. Moertel CG et al. (1993) An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270:943–947

    Article  PubMed  CAS  Google Scholar 

  33. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC (1988) Adjuvant therapy of colorectal cancer. J Am Med Assoc 259:3571–3578

    Article  CAS  Google Scholar 

  34. Guillem JG (1997) Surgical treatment of colorectal cancer. CA Cancer J Clin 47: 113–128

    Article  PubMed  CAS  Google Scholar 

  35. Nordlinger BG, Guiguet M, Vaillant J et al. (1996) Surgical resection of colorectal carcinoma metastases to the liver. Cancer 77:1254–1262

    Article  PubMed  CAS  Google Scholar 

  36. McCormack PM, Burt ME, Bains MS et al. (1992) Lung resection for colorectal metastases: 10-year results. Arch Surg 127:1403–1406

    Article  PubMed  CAS  Google Scholar 

  37. Blijham GH (1991) Chemotherapy of colorectal cancer. Anti-Cancer Drugs 2:233–245

    Article  PubMed  CAS  Google Scholar 

  38. Moertel CG (1994) Chemotherapy for Colorectal Cancer. N Engl J Med 330:1136–1142

    Article  PubMed  CAS  Google Scholar 

  39. Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10:896–903

    Google Scholar 

  40. Advanced Colorectal Cancer Meta-analysis Project (1994) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12:960–969

    Google Scholar 

  41. Laufmann LR, Bukowski RM, Collier MA et al. (1993) A randomized double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 11:1888–1893

    Google Scholar 

  42. Poon MA, O’Connell MJ, Wieand HS et al. (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967–1972

    PubMed  CAS  Google Scholar 

  43. Petrelli N, Herrera L, Rustum Y et al. (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluoro-uracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559–1565

    PubMed  CAS  Google Scholar 

  44. Valone FH, Friedman MA, Wittlinger PS et al. (1989) Treatment of patients with advanced colorectal carcinoma with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil and leucovorin; a randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427–1436

    PubMed  CAS  Google Scholar 

  45. Glimelius B (1993) Biochemical modulation of 5-Fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 4:235–240

    PubMed  CAS  Google Scholar 

  46. Buroker TR, O’Connell MJ, Wieand HS et al. (1994) Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14–20

    PubMed  CAS  Google Scholar 

  47. Labianca R, Cascinu S, Frontini L et al. (1997) High versus low dose levoleucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A GISCAD phase III study. Ann Oncol 8:169–174

    Article  PubMed  CAS  Google Scholar 

  48. Jäger E, Heike M, Bernard H et al. (1996) Weekly high-dose leucovorin versus low-dose, leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. J Clin Oncol 14:2274–2279

    PubMed  Google Scholar 

  49. Scheithauer W, Kornek G, Marczell A et al. (1997) Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III. J Clin Oncol 15:908–914

    PubMed  CAS  Google Scholar 

  50. Brook J (1995) Fluorouracil and low-dose leucovorin versus fluorouracil and high-dose leucovorin. What is the real cost? What is the answer. J Clin Oncol 13 : 1830–1831

    PubMed  CAS  Google Scholar 

  51. Poon MA, O’Connell MJ, Moertel CG et al. (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407–1418

    PubMed  CAS  Google Scholar 

  52. Wadler S, Schwartz EL, Goldman M et al. (1989) Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal cancer. J Clin Oncol 7:1769–1775

    PubMed  CAS  Google Scholar 

  53. Corfu-A study group (1995) Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921–928

    Google Scholar 

  54. Hill M, Norman A, Cunningham D et al. (1995) Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 13:1297–1302

    PubMed  CAS  Google Scholar 

  55. Seymour MT, Slevin ML, Kerr D et al. (1996) Randomized trial assessing the addition of interferon alfa-2a to fluorouracil and leucovorin in advanced colorectal cancer. J Clin Oncol 14:2280–2288

    PubMed  CAS  Google Scholar 

  56. Greco FA, Figlin R, York M et al. (1996) Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14:2674–2681

    PubMed  CAS  Google Scholar 

  57. Kosmidis PA, Tsavaris N, Skarlos D et al. (1996) Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. J Clin Oncol 14:2682–2687

    PubMed  CAS  Google Scholar 

  58. Wils JA (1992) High-dose fluorouracil: a new perspective in the treatment of colorectal cancer? Sem Oncol: 19(Suppl 3) : 126–130

    CAS  Google Scholar 

  59. Sobrero A, Aschele C, Bertino J (1997) Fluorouracil in colorectal cancer. A tale of two drugs: implications for biochemical modulation. J Clin Oncol 15:368–381

    PubMed  CAS  Google Scholar 

  60. Lokich JJ, Ahlgren JD, Gullo JJ et al. (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7:425–432

    PubMed  CAS  Google Scholar 

  61. Rougier PH, Paillot B, Laplance A et al. (1992) End results of a multicentric randomized trial comparing 5-FU in continuous systemic infusion (CI) to bolus administration (B) in measurable metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 11:163

    Google Scholar 

  62. De Gramont A, Bosset JF, Milon C et al. (1997) Randomized trial comparing monthly low dose leucovorin and Fluorouracil bolus with bimonthly high-dose leucovorin and Fluorouracil bolus plus continuous infusion for advanced colorectal cancer. A French Intergroup Study. J Clin Oncol 15:808–815

    PubMed  Google Scholar 

  63. Blijham GH, Wagener T, Wils J et al. (1996) Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer. Final results of a randomized European Organisation for Research and Treatment of Cancer study. J Clin Oncol 14:2266–2273

    PubMed  CAS  Google Scholar 

  64. Aranda E, Cervantes A, Anton A et al. (1997) A phase III multicenter randomized study in advanced colorectal cancer: fluorouracil high dose continuous infusion weekly versus fluorouracil + leucovorin. Preliminary results. Proc Am Soc Clin Oncol 16:281a

    Google Scholar 

  65. Köhne C, Schöffski P, Wilke H et al. (1997) Biochemical modulation of weekly high-dose infusional (HD-CI) 5-FU in patients with advanced colorectal cancer. Results of a multicenter randomized AIO trial. Proc Am Soc Clin Oncol 16:271 a

    Google Scholar 

  66. Ross P, Norman A, Cunningham et al. (1997) A prospective randomised trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer. Proc Am Soc Clin Oncol 16:271 a

    Google Scholar 

  67. Rougier P, Buyse M, Ryan L, Hansen R (1997) Meta-analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients wieth advanced colorectal cancer. Proc Am Soc Clin Oncol 16:267a

    Google Scholar 

  68. Ross PF, Webb A, Cunningham D et al. (1997) Infusional 5-fluorouracil in the treatment of gastrointestinal cancer: the Royal Marsden Hospital experience. Ann Oncol: 111–116

    Google Scholar 

  69. Leichman CG, Fleming TR, Muggia FM et al. (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncolog Group Study. J Clin Oncol 13:1303–1311

    PubMed  CAS  Google Scholar 

  70. Blijham GH, Wagener TH, Wils J et al. (1997) Double modulation of high-dose 5-fluorouracil (FU) with low-dose PALA and methotrexate (MTX): results of a randomized EORTC study. Proc Am Soc Clin Oncol 16:267 a

    Google Scholar 

  71. Van Cutsem E (1996) A glimpse of the future. New directions in the treatment of colorectal cancer. Eur J Cancer 32 A(Suppl 5) :S 23–27

    Article  Google Scholar 

  72. Bleiberg H (1997) Colorectal cancer. Is there an alternative to 5-FU? Eur J Cancer 33:536–541

    Article  PubMed  CAS  Google Scholar 

  73. Cunningham D, Zalcberg J, Rath U et al. (1997) Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-Fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7:961–965

    Article  Google Scholar 

  74. Pazdur R, Vincent M (1997) Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 16:228 a

    Google Scholar 

  75. Harper P (1997) Advanced colorectal cancer (ACC): results from the latest Tomudex® (raltitrexed) comparative study. Proc Am Soc Clin Oncol 16: 228a

    Google Scholar 

  76. Cripps MC, Burnfeld M, Jolivet J et al. (1997) Phase II study of a multi-targeted antifolate (LY23 1514) (MTA) as first-line therapy in patients with locally advanced or metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 16:267a

    Google Scholar 

  77. Rougier P, Bugat R, Douillard JY et al. (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251–260

    PubMed  CAS  Google Scholar 

  78. Rothenberg ML, Eckhardt JR, Kuhn JG et al. (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128–1135

    PubMed  CAS  Google Scholar 

  79. Conti JA, Kemeny N, Saltz L et al. (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709–715

    PubMed  CAS  Google Scholar 

  80. Van Cutsem E, Rougier PH, Doz JP et al. (1997) Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer resistant to 5-FU. Proc Am Soc Clin Oncol 16:268 a

    Google Scholar 

  81. Abigerges D, Armand JP, Chabot GG et al. (1994) Irinotecan (CPT-11) high-dose escalation using high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446–449

    Article  PubMed  CAS  Google Scholar 

  82. Malik STA, Talbot D, Clarke PI et al. (1990) Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 62:1023–1025

    Article  PubMed  CAS  Google Scholar 

  83. Pazdur R, Lassere Y, Rhodes V et al. (1994) Phase II trial of Uracil and Tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296–3000

    PubMed  CAS  Google Scholar 

  84. González Barón M, Feliu J, de la Gándara I et al. (1995) Efficacy of oral Tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 31:2215–2219

    Article  Google Scholar 

  85. Saltz LB, Leichman CF, Young CW et al. (1995) A fixed-ratio combination of uracil and ftorafur (UFT®) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 75:782–785

    Article  PubMed  CAS  Google Scholar 

  86. Peters GJ, Van Groeningen CJ, Schornagel JH et al. (1997) Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5-FU)-based antineoplastic agent. Proc Am Soc Clin Oncol 15:227 a

    Google Scholar 

  87. Schildky R, Bukowski R, Burris H et al. (1997) A phase II study of a five day regimen of oral 5-fluorouracil (5-FU) plus GW776 (776C85) with or without leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 16:171 a

    Google Scholar 

  88. Findlay M, Van Cutsem E, Kocha W et al. (1997) A randomised phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 16:227a

    Google Scholar 

  89. Brown TD, Fleming TR, Goodman PJ et al. (1995) A randomized trial of two schedules of trimetrexate versus 5-Fluorouracil in advanced colorectal cancer: a SWOG Study. Anticancer Drugs 6:219–223

    Article  PubMed  CAS  Google Scholar 

  90. Romanini A, Li WW, Colofiore JR, Bertino JR (1992) Leucovorin enhaces cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil in CCRF-CEM cells. J Nat Cancer Inst 84:1033–1038

    Article  PubMed  CAS  Google Scholar 

  91. Conti JA, Kemeny N, Seiter K et al. (1994) Trial of sequential trimetrexate, fluorouracil and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 12:695–700

    PubMed  CAS  Google Scholar 

  92. Blanke CD, Kasimis B, Schein P et al. (1997) Phase II study of trimetrexate, fluorouracil and leucovorin for advanced colorectal cancer. J Clin Oncol 15:915–920

    PubMed  CAS  Google Scholar 

  93. Machover D, Diaz-Rubio E, de Gramont et al. (1996) Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95–98

    Article  PubMed  CAS  Google Scholar 

  94. Bécouarn Y, Ychou M, Ducreux M et al. (1997) Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc Am Soc Clin Oncol 16:229 a

    Google Scholar 

  95. De Gramont A, Vignoud J, Tournigand C et al. (1997) Oxaliplatin with high-dose leucovorin and 5-Fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214–219

    Article  PubMed  Google Scholar 

  96. Lévi F, Zidani R, Vannetzel MJ et al. (1994) Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J Natl Cancer Inst 86:1608–1617

    Article  PubMed  Google Scholar 

  97. Giacchetti S, Zidani R, Perpoint B et al. (1997) Phase III trial of 5-fluorouracil (5-FU) folinic acid (FA, with or without oxaliplatin (OXA) in previously untreated patients (PTS) with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 16:229a

    Google Scholar 

  98. Bertheault-Cvitkovic F, Jami A, Ithzakin M et al. (1996) Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 14:2950–2958

    PubMed  CAS  Google Scholar 

  99. Lévi F, Dogliotti L, Perpoint B et al. (1997) A multicenter phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with previously untreated metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 16:266a

    Google Scholar 

  100. Laurie JA, Moertel CG, Fleming TR et al. (1989) Surgical adjuvant therapy of large bowel carcinoma: An evaluation of levamisole and the combination of levamisole and 5-fluorouracil. J Clin Oncol 7:1447–1456

    PubMed  CAS  Google Scholar 

  101. Moertel CG, Fleming TR, MacDonald JS et al. (1990) Levamisole and fluorouracil for surgical adjuvant therapy of colon carcinoma. N Engl J Med 322:352–358

    Article  PubMed  CAS  Google Scholar 

  102. Moertel CG, Fleming TR, MacDonald J et al. (1992) The intergroup study of 5-FU plus lev and levamisole alone as adjuvant therapy for stage C colon cancer: A final report. Proc Am Soc Clin Oncol 11:161

    Google Scholar 

  103. Wolmark N, Rockette H, Fisher B et al. (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy of primary colon cancer: Results from the NSABP protocol C-03. J Clin Oncol 11:1879–1887

    PubMed  CAS  Google Scholar 

  104. Marsoni S (for the IMPACT investigators) (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939–944

    Article  Google Scholar 

  105. O’Connell MJ, Mailliard JA, Kahn MJ et al. (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250

    PubMed  Google Scholar 

  106. Francini G, Perioli R, Lorenzini L et al. (1994) Folinic acid and 5-fluorouracil as adjuvant chemotheray in colon cancer. Gastroenterology 106:899–906

    PubMed  CAS  Google Scholar 

  107. Moertel CG, Fleming TR, MacDoanld JS et al. (1993) Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 11:2386–2390

    PubMed  CAS  Google Scholar 

  108. Wolmark N, Rockette H, Mamounas EP et al. (1996) The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-Lev) and 5-FU + leucovorin + levamisole (FU-LV-Lev) in patients with Duke’s B and C carcinoma of the colon: first report of NSABP C-04. Proc Am Soc Clin Oncol 15:205

    Google Scholar 

  109. Haller DG, Catalano PJ, Macdonald JS et al. (1996 and 1997) Fluorouracil (FU), leucovorin (LV) and levamisole (lev) adjuvant therapy for colon cancer: preliminary results of INT-0089. Proc Am Soc Clin Oncol 15:21,

    Google Scholar 

  110. Haller DG, Catalano PJ, Macdonald JS et al. (1996 and 1997) Fluorouracil (FU), leucovorin (LV) and levamisole (lev) adjuvant therapy for colon cancer: preliminary results of INT-0089. Proc Am Soc Clin Oncol 16:265a

    Google Scholar 

  111. O’Connell MJ, Laurie JA, Shepherd L et al. (1996) A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 15:209

    Google Scholar 

  112. National Institutes of Health Consensus Development Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444–1450

    Article  Google Scholar 

  113. Taylor I, Machin D, Mullee M et al. (1985) A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 72:359–363

    Article  PubMed  CAS  Google Scholar 

  114. Wereldsma JCJ, Bruggink EDM, Meyer WS et al. (1990) Adjuvant portal liver infusion in colorectal cancer with 5-Fluorouracil/heparin versus urokinase versus control. Cancer 65:425–432

    Article  PubMed  CAS  Google Scholar 

  115. Beart RW, Moertel CG, Wieand HS et al. (1990) Adjuvant therapy for resectable colorectal carcinoma with 5-Fluorouracil administered by portal infusion. Arch Surg 125:897–901

    Article  PubMed  Google Scholar 

  116. Wolmark N, Rockette H, Wickerham DL et al. (1990) Adjuvant therapy of Dukes’ A, B and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of NSABP protocol C-02. J Clin Oncol 8:1466–1475

    PubMed  CAS  Google Scholar 

  117. Wolmark N, Rockette H, Petrelli N et al. (1994) Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer. NSABP C-02. Proc Am Soc Clin Oncol 13:194

    Google Scholar 

  118. Metzger U, Laffer U, Castiglione M et al. (1989) Adjuvant intraportal chemotherapy for colorectal cancer. Four year results of the randomized Swiss study. Proc Am Soc Clin Oncol 8:105

    Google Scholar 

  119. Fielding LP, Hittinger R, Grace RH et al. (1992) Randomized controlled trial of adjuvant chemotherapy by portal vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 340:502–506

    Article  PubMed  CAS  Google Scholar 

  120. Piedbois P, Buyse M, Gray I et al. (1995) Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc Am Soc Clin Oncol 14:192

    Google Scholar 

  121. Crowley JJ (1994) Perioperative portal vein chemotherapy. ASCO Educational Book, pages 171–175

    Google Scholar 

  122. Nordic Gastrointestinal Tumor Adjuvant Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10:904–911

    Google Scholar 

  123. Scheithauer W, Rosen H, Korneck GV et al. (1993) Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752–755

    Article  PubMed  CAS  Google Scholar 

  124. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J (1994) Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344:1255–1260

    Article  PubMed  CAS  Google Scholar 

  125. Hafström L, Engarås B, Holmberg ST et al. (1994) Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A Randomized Clinical Trial. Cancer 74:2749–2756

    Article  PubMed  Google Scholar 

  126. Glimelius B (1993) Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 4:235–240

    PubMed  CAS  Google Scholar 

  127. Blijham GH (1997) Should patients with advanced colorectal cancer be treated with chemotherapy? Eur J Cancer 33:815–817

    Article  PubMed  CAS  Google Scholar 

  128. Kemeny NE (1992) Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes! In: DeVita V, Hellman S, Rosenberg SA (eds) Important Advanced in Oncology. JB Lippincott, Philadelphia pp 207–227

    Google Scholar 

  129. O’Connell MJ (1992) Is hepatic infusion of chemotherapy effective treatment for liver metastases? No! In: DeVita V, Hellman S, Rosenberg SA (eds) Important Advances in Oncology. J.B. Lippincott, Philadelphia, pp 228–234

    Google Scholar 

  130. Goldberg RM, Hatfield AK, O’Connell MJ, Mahoney M, Krook JE (1997) Salvage 5-FU-based chemotherapy (CT) for patients (pts) with advanced colorectal cancer (CRC) who have relapsed following surgical adjuvant (ADJ) CT: A North Central Cancer Treatment Group Trial. Proc Am Soc Clin Oncol 16:271 a

    Google Scholar 

  131. MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457–460

    Article  PubMed  CAS  Google Scholar 

  132. Higgins GA, Humphrey EW, Dwight TW et al. (1986) Preoperative radiation and surgery for cancer of the rectum: Veterans Administration Surgical Oncology Group Trial 11. Cancer 58:352–359

    Article  PubMed  CAS  Google Scholar 

  133. Gerard A, Buyse M, Norlinger B et al. (1988) Pre-operative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 208:606–614

    Article  PubMed  CAS  Google Scholar 

  134. Dahl O, Horn A, Morild I et al. (1990) Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Cancer 66:2286–2294

    Article  PubMed  CAS  Google Scholar 

  135. Stockholm Rectal Cancer Study Group (1990) Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer 66:49–55

    Article  Google Scholar 

  136. Gastrointestinal Tumor Study Group (1985) Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 312:1465–1472

    Article  Google Scholar 

  137. Gastrointestinal Tumor Study Group (1986) Survival after post operative combination treatment of rectal cancer. N Engl J Med 315:1294–1295

    Article  Google Scholar 

  138. Balslev I, Pederson M, Teglbjaerg PS et al. (1986) Post-operative radiotherapy in Dukes’ B and C carcinoma of the rectum and rectosigmoid. Cancer 58: 22–28

    Article  PubMed  CAS  Google Scholar 

  139. Fisher B, Wolmark N, Rockette H et al. (1988) Postoperative adjuvant chemotherapy or radiotherapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 80:21–29

    Article  PubMed  CAS  Google Scholar 

  140. Treurniet-Donker AD, Van Putten LJ, Wereldsma JC et al. (1991) Postoperative radiation therapy for rectal cancer. Cancer 67:2042–2048

    Article  PubMed  CAS  Google Scholar 

  141. Pahlman L, Glimelius B (1990) Pre- or post-operative radiotherapy in rectal and recto-sigmoid carcinoma. Ann Surg 211:187–195

    Article  PubMed  CAS  Google Scholar 

  142. Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987

    Article  Google Scholar 

  143. Holm T, Singnomklao T, Rutqvist LE, Cdermark B (1996) Adjuvant preoperative radiotherapy in patients with rectal carcinoma: adverse effects during long term follow-up of two randomized trials. Cancer 78:968–976

    Article  PubMed  CAS  Google Scholar 

  144. Frykholm GJ, Glimelius B, Pahlman L (1993) Preoperative or postoperative irradiation in adonocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 36:564–572

    Article  PubMed  CAS  Google Scholar 

  145. Minsky B (1997) Adjuvant therapy for rectal cancer — a good first step. N Engl J Med 336:1016–1017

    Article  PubMed  CAS  Google Scholar 

  146. Krook JE, Moertel CG, Gunderson LL et al. (1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Eng J Med 324:709–715

    Article  CAS  Google Scholar 

  147. Rockette H, Deutsch M, Petrelli N et al. (1994) Effect of postoperative radiation therapy (RTX) when used with adjuvant chemotherapy in Dukes’ B and C rectal cancer: results from NSABP R-02. Proc Am Soc Clin Oncol 13:193

    Google Scholar 

  148. Wils J, Wagener DJTh (1992) Combined modality adjuvant treatment of high-risk rectal cancer: a treatment of choice or a choice of treatment? Ann Oncol 3:192–199

    Google Scholar 

  149. Gastrointestinal Tumor Study Group (1992) Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 10:549–557

    Google Scholar 

  150. O’Connell MJ, Martenson J, Wieand H et al. (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–507

    Article  PubMed  Google Scholar 

  151. Tepper JE, O’Connell MJ, Petroni GR et al. (1997) Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of Intergroup 0114. J Clin Oncol 15:2030–2039

    PubMed  CAS  Google Scholar 

  152. Gunderson LL (1994) Adjuvant therapy for rectal cancer. ASCO Eductational Book, pp 162–170

    Google Scholar 

  153. Minsky B, Cohen A, Enker W et al. (1993) Preoperative 5-FU, low dose leucovorin and concurrent radiation therapy for rectal cancer. Proc Am Soc Clin Oncol 12:194

    Google Scholar 

  154. Rietmüller G, Schneider-Gädicke E, Schlimok G et al. (1994) Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 343:1177–1183

    Article  Google Scholar 

Download references

Authors
  1. G. H. Blijham
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Blijham, G.H. (1998). Kolorektales Karzinom. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation